BPTH

Bio-Path Holdings, Inc.

Healthcare · USD

Set alert

Price alert · BPTH

All alert types
0.00 USD 0.00 0.00%
As of Oct 29, 2026 Extended hours 0.21 +71,300.00%
Bid
0.21 × 27,900
Ask
0.21 × 10,000
0.0001 Day range 0.0001
0.0001 52-week range 0.09853
YTD
-99.50%
1 year
-99.67%
Open
0.0001
Prev close
0.0003
Mkt cap
15.09K
Vol
104
Avg vol
33.73K
EPS
-1.14
P/E
0.00
Div yield
0.00%
More statistics
Low
0.0001
High
0.0001
Forward P/E
-0.26
Beta
0.22
Short ratio
0.03
Inst. own
1.08%
Dividend
0.00
Ex-div date
Earnings
Mar 8, 2024
50-d avg
0.8966
200-d avg
1.90
1y target
12.00

5D chart

Chart tools
Interval

Chart is warming up

The five-day price history for BPTH has not been loaded yet. Try again in a moment.

Discussion (15)

Sign in to join the discussion

VICKY HANUKA BPTH 3 years ago #1

On this up is the information I paid for this up 300$ a year it specifically for pharmaceutical

VICKY HANUKA BPTH 3 years ago #2

This is original just now the information
Don’t try to manipulate the bulls

VICKY HANUKA BPTH 3 years ago #3

Push it up it past phase 2 I have special app for pharmaceutical

VICKY HANUKA BPTH 3 years ago #4

ecent Corporate Highlights

Announced Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia. In August, Bio-Path reported positive interim data from Stage 2 of the Company's Phase 2 study of prexigebersen in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia (AML). Prexigebersen continues to be well-tolerated and has now shown compelling efficacy results in two reporting cohorts including evaluable newly diagnosed AML patients and evaluable refractory/relapsed AML patients, which exceed outcomes with combination treatment of decitabine and venetoclax.

VICKY HANUKA BPTH 3 years ago #5

ecent Corporate Highlights

Announced Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia. In August, Bio-Path reported positive interim data from Stage 2 of the Company's Phase 2 study of prexigebersen in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia (AML). Prexigebersen continues to be well-tolerated and has now shown compelling efficacy results in two reporting cohorts including evaluable newly diagnosed AML patients and evaluable refractory/relapsed AML patients, which exceed outcomes with combination treatment of decitabine and venetoclax.

VICKY HANUKA BPTH 3 years ago #6

01/08/2023 07:00AM ET
Bio-Path Holdings Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia

Hedge arsonist BPTH 5 years ago #7

Buy $TYME. Hear me out. New ceo and 100m share offering. Same week they patent covid oral cure. cup and handle is being formed. Reason for red day. Past 3.18 this will blast multiples. Please do your dd and thank me later.
P.s. the new ceo of TYME is the one the ceo that sold the current cure to Pfizer. So........

Hedge arsonist BPTH 5 years ago #8

Buy $TYME. Hear me out. New ceo and 100m share offering. Same week they patent covid oral cure. cup and handle is being formed. Reason for red day. Past 3.18 this will blast multiples. Please do your dad and thank me later.
P.s. the new ceo of TYME is the one the ceo that sold the current cure to Pfizer. So........